EFPIA - European Federation of Pharmaceutical Industries and...

Belkins
The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 33 national associations and 41 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Related News

PREPARATION PRODUCTS OF YILING PHARMA APPROVED BY FDA FOR LAUNCH IN THE US MARKET

Yiling Pharmaceutical Co | September 19, 2020

news image

Yiling Pharmaceutical Co., Ltd. announced on Friday that it had received the approvals of the Abbreviated New Drug Applications (ANDA) about Lisinopril Tablets and Acyclovir Capsules, from United States Food and Drug Administration (hereinafter referred to as the "FDA"), which were submitted by Yiling Wanzhou International Pharmaceutical Co., Ltd., one of the wholly-owned subsidiaries of Yiling Pharmaceutical Co., Ltd., meaning that these products are approved to be produced and sold i...

Read More

PHARMACY MARKET

LILLY AND LYCIA THERAPEUTICS ENTER INTO STRATEGIC COLLABORATION TO DISCOVER AND DEVELOP NOVEL LYSOSOMAL TARGETING CHIMERA (LYTAC) DEGRADERS

Eli Lilly and Company | August 25, 2021

news image

Eli Lilly and Company and Lycia Therapeutics, Inc. today announced a multi-year research collaboration and licensing agreement focused on the discovery, development and commercialization of novel targeted therapeutics using Lycia's proprietary lysosomal targeting chimera, or LYTAC, protein degradation technology. Lycia uses its next-generation degradation approach to target the untapped extracellular proteome, including cell surface receptors and secreted proteins. The LYTAC p...

Read More

PHARMA TECH

PIRAMAL PHARMA SOLUTIONS ANNOUNCES STERILE FILL/FINISH PROGRAM THERATECHNOLOGIES INC

Piramal Pharma Solutions, Theratechnologies Inc. | January 25, 2021

news image

Piramal Pharma Limited's Pharma Solutions business, a leading contract development and manufacturing organization (CDMO), today declared that it is giving Theratechnologies Inc. with GMP manufacturing of sterile fill/finish drug item to help their developmental item as it goes into a first-in-people clinical investigation. The clinical material is being created at the Piramal Pharma Solutions (PPS) manufacturing site in Lexington, Kentucky, which is perceived around the world ...

Read More

BUSINESS INSIGHTS

XERIS PHARMACEUTICALS STRENGTHENS ITS PATENT ESTATE

XERIS PHARMACEUTICALS, INC. | August 20, 2021

news image

Xeris Pharmaceuticals, Inc., a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that it has recently been granted three new patents relating to its formulation technology platforms. The U.S. Patent and Trademark Office granted U.S. Patent Nos. 10,987,399 and 11,020,403 to Xeris, and the China Intellectual Property Office granted Chinese Patent No. ZL201580042185.5 to ...

Read More
news image

PREPARATION PRODUCTS OF YILING PHARMA APPROVED BY FDA FOR LAUNCH IN THE US MARKET

Yiling Pharmaceutical Co | September 19, 2020

Yiling Pharmaceutical Co., Ltd. announced on Friday that it had received the approvals of the Abbreviated New Drug Applications (ANDA) about Lisinopril Tablets and Acyclovir Capsules, from United States Food and Drug Administration (hereinafter referred to as the "FDA"), which were submitted by Yiling Wanzhou International Pharmaceutical Co., Ltd., one of the wholly-owned subsidiaries of Yiling Pharmaceutical Co., Ltd., meaning that these products are approved to be produced and sold i...

Read More
news image

PHARMACY MARKET

LILLY AND LYCIA THERAPEUTICS ENTER INTO STRATEGIC COLLABORATION TO DISCOVER AND DEVELOP NOVEL LYSOSOMAL TARGETING CHIMERA (LYTAC) DEGRADERS

Eli Lilly and Company | August 25, 2021

Eli Lilly and Company and Lycia Therapeutics, Inc. today announced a multi-year research collaboration and licensing agreement focused on the discovery, development and commercialization of novel targeted therapeutics using Lycia's proprietary lysosomal targeting chimera, or LYTAC, protein degradation technology. Lycia uses its next-generation degradation approach to target the untapped extracellular proteome, including cell surface receptors and secreted proteins. The LYTAC p...

Read More
news image

PHARMA TECH

PIRAMAL PHARMA SOLUTIONS ANNOUNCES STERILE FILL/FINISH PROGRAM THERATECHNOLOGIES INC

Piramal Pharma Solutions, Theratechnologies Inc. | January 25, 2021

Piramal Pharma Limited's Pharma Solutions business, a leading contract development and manufacturing organization (CDMO), today declared that it is giving Theratechnologies Inc. with GMP manufacturing of sterile fill/finish drug item to help their developmental item as it goes into a first-in-people clinical investigation. The clinical material is being created at the Piramal Pharma Solutions (PPS) manufacturing site in Lexington, Kentucky, which is perceived around the world ...

Read More
news image

BUSINESS INSIGHTS

XERIS PHARMACEUTICALS STRENGTHENS ITS PATENT ESTATE

XERIS PHARMACEUTICALS, INC. | August 20, 2021

Xeris Pharmaceuticals, Inc., a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that it has recently been granted three new patents relating to its formulation technology platforms. The U.S. Patent and Trademark Office granted U.S. Patent Nos. 10,987,399 and 11,020,403 to Xeris, and the China Intellectual Property Office granted Chinese Patent No. ZL201580042185.5 to ...

Read More

Resources

resource image

PHARMACY MARKET

A pharma outsourcing mission

Article

resource image

BUSINESS INSIGHTS

2021 global life sciences outlook

infographic

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us